The breakthrough in primary human hepatocytes in vitro expansion

References

1. 1.↵
   2. Bernal W,
   3. Jalan R,
   4. Quaglia A,
   5. Simpson K,
   6. Wendon J,
   7. Burroughs A.

   Acute-on-chronic liver failure. Lancet. 2015; 386: 1576–87.

   OpenUrlPubMed
2. 2.↵
   2. Bhatia SN,
   3. Underhill GH,
   4. Zaret KS,
   5. Fox IJ.

   Cell and tissue engineering for liver disease. Sci Transl Med. 2014; 6: 245sr2.

   OpenUrlFREE Full Text
3. 3.↵
   2. Khetani SR,
   3. Bhatia SN.

   Microscale culture of human liver cells for drug development. Nat Biotechnol. 2008; 26: 120–6.

   OpenUrlCrossRefPubMedWeb of Science
4. 4.↵
   2. Kidambi S,
   3. Yarmush RS,
   4. Novik E,
   5. Chao PY,
   6. Yarmush ML,
   7. Nahmias Y.

   Oxygen-mediated enhancement of primary hepatocyte metabolism, functional polarization, gene expression, and drug clearance. Proc Natl Acad Sci USA. 2009; 106: 15714–9.

   OpenUrlAbstract/FREE Full Text
5. 5.↵
   2. Kobayashi N,
   3. Fujiwara T,
   4. Westerman KA,
   5. Inoue Y,
   6. Sakaguchi M,
   7. Noguchi H, et al.

   Prevention of acute liver failure in rats with reversibly immortalized human hepatocytes. Science. 2000; 287: 1258–62.

   OpenUrlAbstract/FREE Full Text
6. 6.↵
   2. Levy G,
   3. Bomze D,
   4. Heinz S,
   5. Ramachandran SD,
   6. Noerenberg A,
   7. Cohen M, et al.

   Long-term culture and expansion of primary human hepatocytes. Nat Biotechnol. 2015; 33: 1264–71.

   OpenUrlCrossRefPubMed
7. 7.↵
   2. Shan J,
   3. Schwartz RE,
   4. Ross NT,
   5. Logan DJ,
   6. Thomas D,
   7. Duncan SA, et al.

   Identification of small molecules for human hepatocyte expansion and iPS differentiation. Nat Chem Biol. 2013; 9: 514–20.

   OpenUrlCrossRefPubMed
8. 8.↵
   2. Katsuda T,
   3. Kawamata M,
   4. Hagiwara K,
   5. Takahashi RU,
   6. Yamamoto Y,
   7. Camargo FD, et al.

   Conversion of terminally committed hepatocytes to culturable bipotent progenitor cells with regenerative capacity. Cell Stem Cell. 2017; 20: 41–55.

   OpenUrlCrossRefPubMed
9. 9.↵
   2. Wu H,
   3. Zhou X,
   4. Fu GB,
   5. He ZY,
   6. Wu HP,
   7. You P, et al.

   Reversible transition between hepatocytes and liver progenitors for in vitro hepatocyte expansion. Cell Res. 2017; 27: 709–12.

   OpenUrl
10. 10.↵
    2. Zhang K,
    3. Zhang LD,
    4. Liu WM,
    5. Ma XL,
    6. Cen J,
    7. Sun Z, et al.

    In vitro expansion of primary human hepatocytes with efficient liver repopulation capacity. Cell Stem Cell. 2018; 23: 806–19.e4.

    OpenUrlPubMed
11. 11.↵
    2. Rezvani M,
    3. Grimm AA,
    4. Willenbring H.

    Assessing the therapeutic potential of lab-made hepatocytes. Hepatology. 2016; 64: 287–94.

    OpenUrlCrossRef
12. 12.↵
    2. Sampaziotis F,
    3. Segeritz CP,
    4. Vallier L.

    Potential of human induced pluripotent stem cells in studies of liver disease. Hepatology. 2015; 62: 303–11.

    OpenUrl
13. 13.↵
    2. Barker RA,
    3. Götz M,
    4. Parmar M.

    New approaches for brain repair-from rescue to reprogramming. Nature. 2018; 557: 329–34.

    OpenUrlCrossRefPubMed
14. 14.↵
    2. Narang AS,
    3. Mahato RI.

    Biological and biomaterial approaches for improved islet transplantation. Pharmacol Rev. 2006; 58: 194–243.

    OpenUrlAbstract/FREE Full Text
15. 15.↵
    2. Lambiv WL,
    3. Vassallo I,
    4. Delorenzi M,
    5. Shay T,
    6. Diserens AC,
    7. Misra A, et al.

    The Wnt inhibitory factor 1 (WIF1) is targeted in glioblastoma and has a tumor suppressing function potentially by induction of senescence. Neuro-Oncol. 2011; 13: 736–47.

    OpenUrlCrossRefPubMed
16. 16.↵
    2. Ferrarelli LK.

    Treating WNT-driven colorectal cancer. Science. 2017; 356: 1346–8.

    OpenUrlFREE Full Text
17. 17.↵
    2. Gregorieff A,
    3. Liu Y,
    4. Inanlou MR,
    5. Khomchuk Y,
    6. Wrana JL.

    Yap-dependent reprogramming of Lgr5⁺ stem cells drives intestinal regeneration and cancer. Nature. 2015; 526: 715–8.

    OpenUrlCrossRefPubMed